Daniel J. Lippis, an insider at Edwards Lifesciences Corp (EW), purchased 23,022 shares of the company on November 9, 2025, at a price of $59.26 per share, totaling approximately $1.36 million. Following this transaction, Lippis holds a total of 23,022 shares in the company.
Edwards Lifesciences, headquartered in Irvine, California, specializes in patient-focused medical innovations for heart disease and critical care monitoring. The company is a leader in transcatheter heart valve replacement technologies, including its renowned Edwards SAPIEN 3 systems. With a market capitalization of $47.9 billion and a P/E ratio of 35.00, Edwards Lifesciences continues to invest in research and development to enhance care for those affected by structural heart disease.
Insider buying often signals confidence in a company's future, as executives typically have access to non-public information regarding their operations. However, investors are advised to consider such transactions as one of many data points in their analysis. Patterns of insider activity across multiple executives can provide more comprehensive insights into the company's outlook than isolated transactions.
The company is scheduled to report its upcoming earnings on April 20, 2026, with an estimated EPS of $0.70 and revenue of $1.6 billion, followed by another report on July 21, 2026, where EPS is estimated at $0.74 and revenue at $1.7 billion.